These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 29552167)

  • 41. Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities.
    Diaz Miqueli A; Blanco R; Garcia B; Badia T; Batista AE; Alonso R; Montero E
    Hybridoma (Larchmt); 2007 Dec; 26(6):423-31. PubMed ID: 18158788
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer.
    Cascone T; Morelli MP; Ciardiello F
    Ann Oncol; 2006 Mar; 17 Suppl 2():ii46-48. PubMed ID: 16608981
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial.
    Ramos TC; Figueredo J; Catala M; González S; Selva JC; Cruz TM; Toledo C; Silva S; Pestano Y; Ramos M; Leonard I; Torres O; Marinello P; Pérez R; Lage A
    Cancer Biol Ther; 2006 Apr; 5(4):375-9. PubMed ID: 16575203
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
    Cappuzzo F; Hirsch FR; Rossi E; Bartolini S; Ceresoli GL; Bemis L; Haney J; Witta S; Danenberg K; Domenichini I; Ludovini V; Magrini E; Gregorc V; Doglioni C; Sidoni A; Tonato M; Franklin WA; Crino L; Bunn PA; Varella-Garcia M
    J Natl Cancer Inst; 2005 May; 97(9):643-55. PubMed ID: 15870435
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
    Raben D; Helfrich B; Bunn PA
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.
    Crombet T; Osorio M; Cruz T; Roca C; del Castillo R; Mon R; Iznaga-Escobar N; Figueredo R; Koropatnick J; Renginfo E; Fernández E; Alvárez D; Torres O; Ramos M; Leonard I; Pérez R; Lage A
    J Clin Oncol; 2004 May; 22(9):1646-54. PubMed ID: 15117987
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
    Giaccone G; Herbst RS; Manegold C; Scagliotti G; Rosell R; Miller V; Natale RB; Schiller JH; Von Pawel J; Pluzanska A; Gatzemeier U; Grous J; Ochs JS; Averbuch SD; Wolf MK; Rennie P; Fandi A; Johnson DH
    J Clin Oncol; 2004 Mar; 22(5):777-84. PubMed ID: 14990632
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting the epidermal growth factor receptor in non-small cell lung cancer.
    Herbst RS; Bunn PA
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5813-24. PubMed ID: 14676101
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.
    Mendelsohn J; Baselga J
    J Clin Oncol; 2003 Jul; 21(14):2787-99. PubMed ID: 12860957
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer.
    Crombet T; Torres L; Neninger E; Catalá M; Solano ME; Perera A; Torres O; Iznaga N; Torres F; Pérez R; Lage A
    J Immunother; 2003; 26(2):139-48. PubMed ID: 12616105
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis.
    Vindeløv LL; Christensen IJ; Nissen NI
    Cytometry; 1983 Mar; 3(5):323-7. PubMed ID: 6188586
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antitumor activity of nimotuzumab in combination with cisplatin in lung cancer cell line A549
    Yang Y; Zhou W; Wu J; Yao L; Xue L; Zhang Q; Wang Z; Wang X; Dong S; Zhao J; Yin D
    Oncol Lett; 2018 Apr; 15(4):5280-5284. PubMed ID: 29552167
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck.
    Crombet Ramos T; Mestre Fernández B; Mazorra Herrera Z; Iznaga Escobar NE
    Front Oncol; 2020; 10():817. PubMed ID: 32537431
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.